共 42 条
- [41] Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (04) : 419 - 427
- [42] Impact on patients' daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)